Nucleus Network News Today

Nucleus Network is helping biotech companies bring their innovations from bench to bedside. Nucleus Network is bringing Australian clinical trial

NEWARK, Del.--(BUSINESS WIRE)--Uvax Bio, LLC, a privately held, clinical-stage vaccine company, today announced acknowledgement from Australian Therapeutic Goods Administration and approval from the

SIOUX FALLS - SAB Biotherapeutics, Inc. , a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing fully-human anti-thymocyte immunoglobulin for...

First subject has been dosed in the first-in-man Phase 1 clinical study of SAB-142, the first fully-human anti-thymocyte immunoglobulin (ATG)

BRISBANE, Australia--(BUSINESS WIRE)--Jun 27, 2023--

The Australian Financial Review: Photos of the Week, June 10, 2023

Blackstone boss Jon Gray says the private capital giant wants to be in ‘good neighbourhoods’ that can deliver cash flow growth in a world where multiples are unlikely to rise.

Recruitment is underway for a pivotal proof-of-concept human trial of The University of Queensland’s second-generation molecular clamp vaccine.

SINGAPORE, March 03, 2023) Novotech research data shows between 2017 and 2021, there were close to 1,400 industry-sponsored single-country vaccine-based clinical trials globally, with the Asia Pacific

Experts Share Insights on Evolving Global Vaccine Landscape Including mRNA TrendsSINGAPORE, March 03, 2023 (GLOBE NEWSWIRE) -- Novotech, the leading Asia Pacific centred biotech CRO with extensive experience in vaccine trials, is convening an expert panel webinar with Endpoints News covering the evolving landscape i...